Trial Profile
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Carcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms APT
- 01 Mar 2023 Results of final 10-year analysis of the open-label, single-arm, phase 2 APT trial assessing long-term outcomes of patients with small, node-negative, HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab and to establish potential biomarkers to predict prognosipublished in the Lancet Oncology
- 31 Aug 2022 Status changed from active, no longer recruiting to completed.
- 11 Apr 2022 Planned End Date changed from 1 Dec 2021 to 1 May 2022.